Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 2/20 | 0.43 |
| ▸ | IDH2 | P48735 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117081 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRALOX15HSD17B10 | |
| SCHEMBL1819250 | 0.81 | ALDH1A1 (0.45) | ALDH1A1CYP3A4TSHRALOX15HSD17B10 | |
| SCHEMBL12096360 | 0.81 | ALDH1A1 (0.45) | ALDH1A1CYP3A4TSHRALOX15HSD17B10 | |
| SCHEMBL966958 | 0.80 | TSHR (0.50) | ALDH1A1CYP3A4TSHRALOX15HSD17B10 | |
| SCHEMBL5272735 | 0.79 | TDP1 (0.43) | ALDH1A1CYP3A4TSHRALOX15HSD17B10 | |
| SCHEMBL12657075 | 0.76 | TDP1 (0.40) | ALDH1A1CYP3A4TSHRALOX15HSD17B10 | |
| Nitrogen SCHEMBL10788887 | 0.75 | ALDH1A1 (0.71) | ALDH1A1CYP3A4TSHRALOX15HSD17B10 | |
| SCHEMBL9181344 | 0.74 | SIGMAR1 (0.63) | CYP3A4TSHRMAPK1LMNASMN1; SMN2 | |
| SCHEMBL172358 | 0.74 | ALDH1A1 (0.77) | ALDH1A1CYP3A4TSHRALOX15HSD17B10 | |
| SCHEMBL8744834 | 0.74 | TDP1 (0.58) | ALDH1A1CYP3A4TSHRALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9753034-B2 | Process for the identification of a compound which inhibits the binding of the first bromodomain of each of human BRD-2, BRD-3, and BRD-4 | GLAXOSMITHKLINE LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-9753034-B2 | Process for the identification of a compound which inhibits the binding of the first bromodomain of each of human BRD-2, BRD-3, and BRD-4 | GLAXOSMITHKLINE LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-9753034-B2 | Process for the identification of a compound which inhibits the binding of the first bromodomain of each of human BRD-2, BRD-3, and BRD-4 | GLAXOSMITHKLINE LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160258946-A1 | NOVEL PROCESS | GLAXOSMITHKLINE LLC | 2016-09-08 | — | — | US | disclosed |
| US-20160258946-A1 | NOVEL PROCESS | GLAXOSMITHKLINE LLC | 2016-09-08 | — | — | US | disclosed |
| US-20160258946-A1 | NOVEL PROCESS | GLAXOSMITHKLINE LLC | 2016-09-08 | — | — | US | disclosed |
| US-9360482-B2 | Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4 | GLAXOSMITHKLINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9360482-B2 | Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4 | GLAXOSMITHKLINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9360482-B2 | Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4 | GLAXOSMITHKLINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| EP-2496558-B1 | TETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1556047-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004032848-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | ALDH1A1 1599/4885CYP3A4 3022/4885TSHR 738/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | ALDH1A1 2039/4885CYP3A4 2852/4885TSHR 800/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | ALDH1A1 1663/4885CYP3A4 3322/4885TSHR 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.